- A 45-year-old woman with long-standing rheumatoid arthritis is treated chronically with high-dose prednisone. She develops new-onset osteoporosis confirmed by dual-energy x-ray absorptiometry. Which of the following drugs directly antagonizes the osteoclast-inducing effect of chronic glucocorticoids by acting as a recombinant form of parathyroid hormone?
Answer: Teriparatide, which given intermittently stimulates osteoblastic bone formation and increases bone mass
When you encounter glucocorticoid-induced osteoporosis questions, focus on the mechanism: chronic steroids suppress osteoblast function and enhance osteoclast activity, leading to net bone loss. The question asks specifically for a drug that's a "recombinant form of parathyroid hormone" - this is your key clue.
Teriparatide (choice A) is synthetic parathyroid hormone that, when given intermittently in low doses, paradoxically stimulates osteoblast activity and bone formation. This directly counteracts glucocoroids' suppression of osteoblasts. While PTH normally increases osteoclast activity when elevated chronically, the intermittent dosing pattern of teriparatide preferentially activates bone-building pathways.
Choice B, denosumab, is indeed effective for glucocorticoid-induced osteoporosis, but it's a monoclonal antibody targeting RANK-L, not a PTH analog. Choice C, alendronate, is a bisphosphonate that works by inducing osteoclast apoptosis - effective but not PTH-related. Choice D, raloxifene, is a SERM that primarily works in postmenopausal women by mimicking estrogen's bone-protective effects, again unrelated to PTH.
The question's wording is crucial here - it explicitly asks for the recombinant PTH form. Even if multiple drugs could treat this patient's osteoporosis, only teriparatide fits the specific molecular description provided.
Study tip: USMLE Step 1 often includes specific molecular descriptions in the question stem that directly point to the answer. When you see "recombinant hormone" or similar terminology, match it exactly to the drug's mechanism rather than just thinking about clinical effectiveness.
- The therapeutic effect of this medication is mediated through its agonist activity at which of the following receptors?
Answer: Dopamine D2 receptors
The patient has a prolactinoma. Prolactin secretion from lactotroph cells in the anterior pituitary is tonically inhibited by dopamine from the hypothalamus. Cabergoline is a potent dopamine D2 receptor agonist. By stimulating D2 receptors on the prolactinoma cells, it mimics the natural inhibitory effect of dopamine, leading to decreased prolactin synthesis and secretion, which restores normal menstrual function and resolves the galactorrhea.
- The addition of fludrocortisone is intended to replace the activity of which of the following deficient hormones?
Answer: Aldosterone
Primary adrenal insufficiency involves destruction of the adrenal cortex, leading to a deficiency of both glucocorticoids (cortisol) and mineralocorticoids (aldosterone). Hydrocortisone replaces cortisol but has insufficient mineralocorticoid activity at physiologic doses. The patient's symptoms of hypotension, salt craving, and hyperkalemia are due to aldosterone deficiency. Fludrocortisone is a potent synthetic mineralocorticoid that acts like aldosterone to increase renal sodium reabsorption and potassium excretion, thereby restoring volume and correcting electrolyte abnormalities.
- A 33-year-old woman with polycystic ovary syndrome is treated with clomiphene citrate to induce ovulation. Which of the following best describes the drug's mechanism in promoting follicular development and ovulation?
Answer: Estrogen receptor antagonism in the hypothalamus blocking negative feedback and increasing GnRH pulse frequency
When approaching questions about fertility medications, focus on understanding how the hypothalamic-pituitary-ovarian axis normally regulates ovulation and where therapeutic interventions disrupt this feedback system.
Clomiphene citrate works by blocking estrogen receptors specifically in the hypothalamus. Normally, rising estrogen levels during the follicular phase provide negative feedback to the hypothalamus, suppressing GnRH release. By antagonizing these estrogen receptors, clomiphene "tricks" the hypothalamus into perceiving low estrogen levels, even when estrogen is present. This removes the negative feedback inhibition, leading to increased GnRH pulse frequency and subsequently higher FSH and LH release from the pituitary. The elevated gonadotropins then stimulate follicular development and ovulation.
Option B describes aromatase inhibitors like letrozole, which block the conversion of androgens to estrogens in granulosa cells. While this can also induce ovulation through reduced estrogen feedback, it's not clomiphene's mechanism. Option C incorrectly suggests direct LH receptor stimulation - clomiphene doesn't act directly on ovarian receptors but works through the hypothalamus. Option D describes what happens with GnRH agonists when given continuously, which actually suppresses ovulation by downregulating pituitary receptors.
Remember that clomiphene is a selective estrogen receptor modulator (SERM) with tissue-specific effects. In the hypothalamus it acts as an antagonist (blocking estrogen's negative feedback), while in other tissues like bone it may act as an agonist. This concept of tissue-specific SERM activity appears frequently on USMLE questions.
- A 55-year-old man with a history of hypertension and heart failure with reduced ejection fraction (HFrEF) develops pain and swelling of both ankles 3 months after starting a new oral diabetes medication. Physical examination reveals bilateral pitting edema without erythema. Which of the following drugs is the most likely cause of his new symptoms?
Answer: Pioglitazone, a PPAR-γ agonist that enhances adipocyte GLUT-4 expression and causes fluid retention
When you encounter a diabetes patient developing new bilateral ankle edema, especially with a history of heart failure, you should immediately think about medication side effects. The key is recognizing which diabetes drugs commonly cause fluid retention.
Pioglitazone (choice A) is a thiazolidinedione that activates PPAR-γ receptors, enhancing insulin sensitivity by increasing GLUT-4 expression in adipocytes. However, this mechanism also increases sodium and water retention in the kidneys, leading to fluid accumulation. This side effect is particularly problematic in patients with existing heart failure, as it can worsen their condition and cause the bilateral pitting edema described.
Choice B (metformin) is incorrect because metformin activates AMPK, reduces hepatic glucose production, and typically causes modest weight loss—not fluid retention. It's actually considered safe in mild heart failure.
Choice C (repaglinide) is wrong because meglitinides work by closing ATP-sensitive potassium channels in pancreatic β-cells to stimulate insulin release. Their main side effect is hypoglycemia, not edema.
Choice D (sitagliptin) is incorrect because DPP-4 inhibitors increase incretin hormone levels and are generally weight-neutral with minimal fluid retention effects.
The correct answer is A because thiazolidinediones like pioglitazone are well-known for causing fluid retention through their renal effects, making them contraindicated or used with extreme caution in heart failure patients.
Study tip: Remember that TZDs (thiazolidinediones) cause "TZ-edema"—this drug class is notorious for fluid retention and should be avoided in heart failure patients.
- An increased risk for which of the following conditions is most associated with this patient's new medication?
Answer: Genitourinary infections
Canagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. These drugs block glucose reabsorption in the proximal renal tubule, leading to glucosuria. The increased glucose in the urine creates a favorable environment for microbial growth, significantly increasing the risk of urinary tract infections and vulvovaginal candidiasis. Lactic acidosis is associated with metformin (B). Agranulocytosis is a rare side effect of thionamides (C). Pancreatitis is a concern with GLP-1 agonists and DPP-4 inhibitors (D).
- A 70-year-old man with long-standing type 2 diabetes is admitted with sepsis and is treated with high-dose glucocorticoids. Within 48 hours his fasting plasma glucose rises to 280 mg/dL despite maximal metformin therapy. Intravenous regular insulin infusion is started. Compared with lispro insulin, regular insulin is preferable in this setting mainly because it:
Answer: Forms hexamers that permit intravenous infusion with a predictable short half-life
When managing severe hyperglycemia in critically ill patients, understanding insulin pharmacokinetics becomes crucial for safe, effective treatment. This question tests your knowledge of why regular insulin remains the gold standard for intravenous infusion despite newer rapid-acting formulations being available.
Regular insulin forms hexamers (six-unit complexes) when concentrated in vial solutions, which makes it uniquely suitable for IV administration. When infused intravenously, these hexamers dissociate predictably into active monomers, providing a consistent, short half-life of about 5-10 minutes. This allows for precise titration and rapid reversal if hypoglycemia occurs - critical safety features when managing unstable glucose levels in septic patients receiving glucocorticoids.
Let's examine why the other options are incorrect: Option B is wrong because regular insulin doesn't have a prolonged peak effect - it actually has a shorter, more predictable action profile when given IV compared to subcutaneous rapid-acting insulins. Option C is incorrect because insulin antibody formation isn't a significant clinical concern with short-term infusions of either insulin type, and there's no meaningful difference between regular and lispro in this regard. Option D is wrong because while insulin does suppress glucagon, this effect isn't meaningfully different between regular and lispro insulin.
For USMLE Step 1, remember that regular insulin's hexamer formation is what makes it the preferred choice for IV infusion. When you see questions about insulin in critical care settings, think about the need for predictable pharmacokinetics and rapid reversibility - this will guide you toward regular insulin for IV use.
- A 24-year-old woman undergoes total thyroidectomy for papillary thyroid carcinoma. Postoperatively she is started on levothyroxine. Six months later her TSH remains elevated despite appropriate dosing based on body weight. She reports taking her pill every morning with coffee on an empty stomach, followed 20 minutes later by omeprazole and a breakfast rich in bran cereal. Which of the following best explains her persistently elevated TSH despite compliance?
Answer: Reduced intestinal absorption of levothyroxine due to concurrent ingestion of coffee and high-fiber cereal
When you encounter a patient with persistently elevated TSH despite appropriate levothyroxine dosing and reported compliance, think systematically about factors that could impair thyroid hormone absorption or metabolism.
Levothyroxine absorption occurs in the small intestine and is highly sensitive to gastrointestinal conditions and concurrent substances. Coffee contains compounds that can bind to levothyroxine and reduce its absorption. Additionally, high-fiber foods like bran cereal can decrease absorption by binding the medication or accelerating intestinal transit time. Even though this patient waits 20 minutes between her levothyroxine and breakfast, coffee taken simultaneously with the medication significantly impairs absorption. The correct answer is A.
B is incorrect because proton pump inhibitors like omeprazole don't directly inhibit deiodinase enzymes. While PPIs can reduce levothyroxine absorption by decreasing gastric acidity (which aids dissolution), this mechanism isn't described in the answer choice.
C is wrong because caffeine doesn't significantly induce cytochrome P-450 enzymes that metabolize levothyroxine. The primary issue with coffee is absorption interference, not enhanced metabolism.
D is incorrect because calcitonin doesn't play a role in thyroid hormone enterohepatic circulation. Calcitonin regulates calcium metabolism and is produced by C-cells, which are removed during thyroidectomy, but this doesn't affect levothyroxine pharmacokinetics.
Study tip: Remember that levothyroxine should be taken on an empty stomach with water only, avoiding coffee, calcium, iron, fiber, and antacids for at least 30-60 minutes. Absorption issues are the most common cause of treatment failure in compliant patients.
- This medication improves the patient's symptoms by acting as a selective agonist at which of the following receptors?
Answer: Vasopressin V2 receptors in the renal collecting ducts
The patient has central diabetes insipidus, characterized by a deficiency of antidiuretic hormone (ADH, or vasopressin). Desmopressin (DDAVP) is a synthetic analog of ADH with high selectivity for the V2 receptor and minimal activity at the V1a receptor. Activation of V2 receptors in the principal cells of the renal collecting ducts stimulates the insertion of aquaporin-2 water channels into the apical membrane, increasing water reabsorption and concentrating the urine.
- The primary mechanism by which this medication increases bone mineral density is by which of the following actions?
Answer: Inducing apoptosis of osteoclasts
Alendronate is a bisphosphonate. Bisphosphonates are pyrophosphate analogs that bind to hydroxyapatite in bone. They are taken up by osteoclasts during bone resorption. Inside the osteoclast, they inhibit farnesyl pyrophosphate synthase, disrupting a key metabolic pathway and inducing osteoclast apoptosis. This reduces bone resorption, allowing osteoblastic activity to predominate, thereby increasing bone mineral density. The specific administration instructions are to prevent esophagitis, a major side effect.
- A 35-year-old woman is diagnosed with Graves disease. She is started on a thioamide drug that rapidly decreases thyroid hormone synthesis by inhibiting thyroid peroxidase and also reduces peripheral conversion of thyroxine (T₄) to triiodothyronine (T₃). Six weeks later she becomes fatigued and febrile; laboratory testing reveals an absolute neutrophil count of 400/µL. Which of the following medications was most likely prescribed?
Answer: Propylthiouracil, which blocks both oxidation/organification of iodide and peripheral T₄→T₃ conversion
When you encounter a question about antithyroid medications, focus on their mechanisms of action and side effect profiles. This question tests your understanding of thioamide drugs used in hyperthyroidism treatment.
The patient presents with classic agranulocytosis (neutrophil count <500/µL) after starting antithyroid therapy. The key clinical clue is that the medication both inhibits thyroid peroxidase AND reduces peripheral T₄→T₃ conversion. This dual mechanism points specifically to propylthiouracil (PTU).
PTU uniquely blocks both thyroid hormone synthesis (by inhibiting thyroid peroxidase-mediated iodide oxidation and organification) and peripheral conversion of T₄ to the more active T₃. This makes it particularly useful in thyroid storm or pregnancy. However, PTU carries a higher risk of severe agranulocytosis compared to methimazole.
Option B describes methimazole, which effectively inhibits thyroid peroxidase but lacks significant peripheral conversion blocking activity. While methimazole can cause agranulocytosis, it doesn't match the described dual mechanism. Option C (propranolol) is a β-blocker that helps with adrenergic symptoms and has some effect on T₄→T₃ conversion, but it's not a thioamide and doesn't inhibit thyroid peroxidase. Option D (potassium iodide) works through the Wolff-Chaikoff effect, temporarily blocking hormone release rather than synthesis.
Remember: PTU has the unique dual mechanism among thioamides but carries higher risks of serious side effects like agranulocytosis and hepatotoxicity. Methimazole is generally preferred except in specific situations like pregnancy or thyroid storm.
- Effective therapy with this medication will most likely result in which of the following changes in her thyroid function tests?
Answer: Decreased TSH, increased free T4
In primary hypothyroidism, the thyroid gland fails, leading to low T4 and a compensatory increase in TSH from the pituitary. Levothyroxine is synthetic T4. Treatment replaces the deficient hormone, increasing free T4 levels. The increased T4 provides negative feedback to the pituitary, which suppresses TSH secretion, bringing it back down into the normal range. Therefore, successful treatment is marked by a decrease in TSH and an increase in free T4.
- A 52-year-old woman with Cushing disease undergoes transsphenoidal resection of an ACTH-secreting pituitary adenoma. Postoperatively she receives high-dose hydrocortisone to prevent adrenal crisis and is later transitioned to physiologic replacement. Long-term systemic glucocorticoid therapy primarily suppresses endogenous cortisol production by which of the following mechanisms?
Answer: Negative feedback on hypothalamic corticotropin-releasing hormone and pituitary ACTH secretion via glucocorticoid receptors
This question tests your understanding of the hypothalamic-pituitary-adrenal (HPA) axis and how exogenous glucocorticoids affect endogenous hormone production. When you encounter questions about hormone replacement or suppression, always think about feedback loops.
Exogenous glucocorticoids like hydrocortisone suppress endogenous cortisol production through the normal negative feedback mechanism. Glucocorticoids bind to receptors in both the hypothalamus and anterior pituitary, inhibiting CRH release from the hypothalamus and ACTH secretion from the pituitary. Without ACTH stimulation, the adrenal cortex reduces cortisol production. This is why patients need gradual tapering after long-term steroid use—their HPA axis needs time to recover function.
Choice A correctly describes this negative feedback mechanism through glucocorticoid receptors at the hypothalamic and pituitary levels.
Choice B is incorrect because glucocorticoids don't directly inhibit 11-β-hydroxylase, the enzyme that converts 11-deoxycortisol to cortisol. The suppression occurs upstream at the hormonal level, not through direct enzyme inhibition.
Choice C confuses glucocorticoid and mineralocorticoid pathways. While glucocorticoids can have some mineralocorticoid effects at high doses, competitive antagonism of mineralocorticoid receptors isn't the mechanism of cortisol suppression.
Choice D is completely incorrect—glucocorticoids don't cause irreversible adrenal destruction. The suppression is functional and reversible, which is why the HPA axis can recover after steroid withdrawal.
Remember: Hormone suppression from exogenous administration almost always involves negative feedback loops, not direct tissue destruction or enzyme inhibition.
- This patient's acute presentation is a direct consequence of the suppression of which of the following?
Answer: Hypothalamic-pituitary-adrenal (HPA) axis
Prolonged use of exogenous glucocorticoids (e.g., prednisone for >3 weeks) suppresses the HPA axis through negative feedback on the hypothalamus (CRH) and pituitary (ACTH). This leads to adrenal cortex atrophy. Abrupt cessation of the steroid unmasks this suppression, resulting in an iatrogenic acute adrenal insufficiency (adrenal crisis) because the atrophied adrenal glands cannot produce enough endogenous cortisol to meet physiologic demands.
- A 63-year-old man with type 2 diabetes mellitus, coronary artery disease, and stage 3 chronic kidney disease (estimated glomerular filtration rate 38 mL/min/1.73 m²) presents for routine follow-up. His current medications include aspirin, lisinopril, atorvastatin, and metformin 1000 mg twice daily. Laboratory studies today show serum creatinine 2.0 mg/dL (baseline 1.7 mg/dL) and HbA1c 7.4%. The physician decides to discontinue metformin and begin an alternative glucose-lowering agent that will improve glycemic control and provide cardiovascular benefit without increasing the risk of hypoglycemia or causing weight gain. Which of the following drugs best meets these goals for this patient?
Answer: Empagliflozin, an SGLT2 inhibitor that promotes glycosuria and lowers cardiovascular mortality
When managing diabetes in patients with chronic kidney disease, you need to consider both glycemic efficacy and renal safety. This patient's worsening creatinine (2.0 mg/dL from baseline 1.7) makes metformin inappropriate, as it increases lactic acidosis risk when eGFR falls below 30-45 mL/min/1.73 m².
A is correct because empagliflozin perfectly matches all the stated criteria. SGLT2 inhibitors block glucose reabsorption in the proximal tubule, promoting glycosuria and lowering HbA1c without causing hypoglycemia (they don't stimulate insulin). They provide proven cardiovascular benefits through reduced heart failure hospitalizations and cardiovascular death, likely via improved hemodynamics and reduced preload. Weight loss occurs due to caloric loss through glucose excretion, and these agents are safe in moderate CKD.
B is wrong because glyburide directly contradicts two requirements: sulfonylureas stimulate pancreatic insulin release, causing hypoglycemia risk, and typically cause weight gain. They also lack cardiovascular benefits.
C is wrong because NPH insulin causes both hypoglycemia (especially overnight) and weight gain due to anabolic effects. While it effectively lowers glucose, it doesn't meet the safety criteria specified.
D is wrong because pioglitazone causes significant fluid retention and weight gain through increased sodium retention and adipogenesis. The fluid retention is particularly problematic in patients with cardiovascular disease.
Study tip: For CKD patients with diabetes, remember that SGLT2 inhibitors offer a "triple benefit" - glucose lowering, cardiovascular protection, and renal protection - making them excellent choices when metformin becomes contraindicated.
- This medication primarily reduces thyroid hormone levels by inhibiting which of the following processes?
Answer: Oxidation and organification of iodide
Methimazole is a thionamide drug that inhibits thyroid peroxidase (TPO). TPO is the key enzyme in thyroid hormone synthesis, responsible for oxidizing iodide to iodine and then incorporating it into tyrosine residues on thyroglobulin (organification). By blocking TPO, methimazole effectively halts the synthesis of new thyroid hormone. It does not block the peripheral conversion of T4 to T3 (B), a property unique to PTU. Iodide uptake (C) is blocked by perchlorate. Release of preformed hormone (D) is inhibited by high doses of iodine.
- Which of the following best describes the mechanism of action of this newly added medication?
Answer: Mimics the action of an endogenous incretin hormone
The description fits a glucagon-like peptide-1 (GLP-1) receptor agonist, such as semaglutide or dulaglutide, which are often administered weekly. These drugs mimic the action of the incretin hormone GLP-1, leading to glucose-dependent insulin release, decreased glucagon secretion, delayed gastric emptying, and increased satiety, which frequently results in weight loss. A long-acting insulin (B) would cause weight gain. Amylin analogs like pramlintide (C) can cause weight loss but are less commonly used. DPP-4 inhibitors (D) are oral agents and are weight-neutral.
- Which of the following best describes the primary mechanism of action of the medication prescribed for this patient?
Answer: Decreases hepatic gluconeogenesis
The first-line oral agent for type 2 diabetes mellitus is metformin. Metformin's primary mechanism of action is the inhibition of hepatic gluconeogenesis. It also increases peripheral glucose uptake and insulin sensitivity, but its main effect is on the liver. The other options describe different classes of antidiabetic drugs: sulfonylureas (B), thiazolidinediones (C), and SGLT2 inhibitors (D).
- The patient's hypoglycemic episode is most likely caused by a medication that acts via which of the following mechanisms?
Answer: Binding to and closing ATP-dependent potassium channels on pancreatic beta cells
The patient is experiencing severe hypoglycemia, a well-known side effect of sulfonylureas like glyburide. Sulfonylureas exert their effect by binding to and closing the ATP-dependent potassium (K-ATP) channels on pancreatic beta cells. This leads to membrane depolarization, calcium influx, and glucose-independent insulin secretion, which carries a high risk of hypoglycemia. DPP-4 inhibitors (B) and GLP-1 agonists (C) have a low risk of hypoglycemia because their action is glucose-dependent. Metformin (D) does not typically cause hypoglycemia when used as monotherapy.
- A 59-year-old man with type 2 diabetes and obesity is started on liraglutide. Four weeks later he reports early satiety, 4-kg weight loss, and occasional post-prandial nausea. Which of the following best describes the principal mechanism by which liraglutide lowers blood glucose in this patient?
Answer: Activation of GLP-1 receptors leading to glucose-dependent insulin secretion and slowed gastric emptying
When you encounter diabetes medications on Step 1, focus on their specific mechanisms and clinical effects. The patient's symptoms—early satiety, weight loss, and post-prandial nausea—are classic GLP-1 receptor agonist effects that help identify the drug's mechanism.
Liraglutide is a GLP-1 receptor agonist that mimics the incretin hormone GLP-1. When you activate GLP-1 receptors, two key things happen: glucose-dependent insulin secretion from pancreatic beta cells and delayed gastric emptying. The "glucose-dependent" aspect is crucial—insulin is only released when blood glucose is elevated, which minimizes hypoglycemia risk. The delayed gastric emptying explains this patient's early satiety and nausea, while also contributing to glucose control by slowing nutrient absorption.
Choice A correctly describes liraglutide's mechanism through GLP-1 receptor activation. Choice B describes α-glucosidase inhibitors like acarbose, which block carbohydrate digestion in the intestine. Choice C describes SGLT2 inhibitors like empagliflozin, which cause glucose loss through urine by blocking renal glucose reabsorption. Choice D describes DPP-4 inhibitors like sitagliptin, which prevent breakdown of endogenous GLP-1 rather than directly activating its receptors.
Remember that incretin-based therapies (GLP-1 agonists and DPP-4 inhibitors) both work through the GLP-1 pathway but differently: agonists directly activate receptors while DPP-4 inhibitors preserve your body's own GLP-1. The key distinguishing feature is that GLP-1 agonists cause significant GI side effects and weight loss, while DPP-4 inhibitors are generally GI-neutral and weight-neutral.
